Zacks Investment Research·Sep 30, 2026
Here's Why You Should Add URGN Stock to Your Portfolio NowUroGen's Zusduri sales surge, Jelmyto revenues and advancing pipeline assets strengthen its shift toward a commercial growth story.
UroGen's ZUSDURI launch has driven a dramatic revenue inflection, with Q2 2026 revenue surging 199.2% year-over-year to $72.5M and the company achieving its first positive operating income of $111K after nine consecutive quarters of losses. However, this growt...
Price trend, volume and key moving averages
Trailing total returns as of 10/10/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | -$0.28-5.7% vs -$0.27 | $72M+14.0% vs $64M |
Q2 2026 May 6, 2026 | -$0.47+16.1% vs -$0.56 | $51M+13.7% vs $45M |
Q2 2026 Mar 2, 2026 | -$0.54-4.2% vs -$0.52 | $38M-5.2% vs $40M |
Q4 2025 Nov 6, 2025 | -$0.69+4.2% vs -$0.72 | $27M-31.5% vs $40M |
UroGen's Zusduri sales surge, Jelmyto revenues and advancing pipeline assets strengthen its shift toward a commercial growth story.
Zoetis (NYSE: ZTS - Get Free Report) and Urogen Pharma (NASDAQ: URGN - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, risk, dividends and valuation. Profitability This table compares Zoetis and Urogen Pharma's net
UroGen Pharma Ltd. has transitioned into a commercial-stage biopharma, driven by strong adoption of Zusduri for recurrent non-muscle invasive bladder cancer. Zusduri achieved an 80% complete response rate in the ENVISION trial, with a 64.5% chance of remaining disease-free at 3 years among responders. URGN-103, a next-generation mitomycin-based product, is positioned to replace Zusduri, offering manufacturing and convenience advantages; NDA submission is complete and approval is likely.
Zacks spotlights Oportun Financial, Uranium Royalty and Amgen, alongside standout gains from its key stock portfolios.
Benchmark URGN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for UroGen Pharma Ltd. (URGN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $36.98 | $1.8B | -11.59 | 21.45% | -139.81% | — | — | |
| $65.02 | $9.39B | -11.55 | — | — | -37.57% | — | |
| $42.14 | $2.45B | -61.97 | 8.63% | -13.23% | -10.42% | — | |
| $14.50 | $2.01B | -1.41 | -2.75% | -41.85% | -55.97% | — | |
| $37.40 | $1.52B | 31.43 | 27.37% | 6.57% | 28.67% | — | |
| $123.96 | $9.13B | -21.19 | — | — | -42.78% | — |
UroGen Pharma Ltd. (URGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
UroGen Pharma Ltd. (URGN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jun 23, 2026·SEC
Jun 2, 2026·SEC
Get notified when URGN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
UroGen Pharma Ltd. (URGN) stock FAQ — growth, dividends, profitability & financials explained
UroGen Pharma Ltd. (URGN) reported $188.7M in revenue for fiscal year 2025.
UroGen Pharma Ltd. (URGN) grew revenue by 21.4% over the past year. This is strong growth.
UroGen Pharma Ltd. (URGN) reported a net loss of $97.6M for fiscal year 2025.
UroGen Pharma Ltd. (URGN) had negative free cash flow of $159.1M in fiscal year 2025, likely due to heavy capital investments.
